Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. Celgene Ongoing Ozanimod HCl 3 RPC01-3201 KAUH-J
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma SWOG (Southwest Oncology Group) Ongoing Ibrutinib 3 A051301 KFSH&RC-R
HELIOS-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) Alnylam Pharmaceuticals. Ongoing ALN-TTRSC02 (Vutrisiran) 3 ALN-TTRSC02-003 King Khalid University Hospital (Riyadh)
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Roche Completed Bevacizumab 3 MO22923 KFMC
Freeze dried kale to go, new superfood supplement to reduce metabolic risk in Saudi subjects The National Plan for Science,Technology and Innovation Ongoing Freeze dried kale 3 H-01-R-002 King Khalid University Hospital (Riyadh)
Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders Bellicum Pharmaceuticals Ongoing Rimiducid 1/2 CT17-008-R NGHA-R
Fluids in Septic Shock: A Randomized control Trial McMaster University Completed Sodium Chloride 3 20120802 King Fahad University Hospital (Al-Khobar)
Fluids in Septic Shock (FISSH): a randomized controlled trial. McMaster University Ongoing Normal Saline & Ringer's Lactate 3 2211076 King Faisal Specialist Hospital and Research Center (Riyadh)
Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 KAIMRC Ongoing TOCILIZUMAB 3 RC20/225/R King Abdulaziz Medical City NG (Riyadh)
Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 KAIMRC Ongoing TOCILIZUMAB 3 RC20/225/R King Abdulaziz Medical City NG (Riyadh)
View 251 - 260 From 756